Abstract
Hypertension is one of the major risk factors for cardiovascular disease and fatal or non-fatal cardiac and cerebrovascular complications. Kidney and retina are also target organs of blood pressure rise. Progressive changes in the definition of hypertension have occurred in the years and blood pressure 130/85 mm Hg is considered as normal.
Ischaemic heart disease, particularly myocardial infarction, often unrecognized, as well as stroke and transient ischaemic attack may be observed more frequently than other disorders in hypertensive patients.
Conducted large-scale trials do not support the hypothesis that effective benefits are reached by current nonpharmacological or pharmacological prevention although some different opinions exist.
Lowering blood pressure is, however, the main target to reach for reducing cardiovascular complications in hypertensive patients, in anyway that can be obtained. So doing, the ratio cost-benefit could be improved with a reduction of the costs supported by public health for hypertensive individuals.
Keywords: Blood Pressure Control, Clinical Trials, Costs, Epidemiological findings, Hypertension, Public Health
Current Hypertension Reviews
Title:The Control of Arterial Hypertension: Epidemiological and Economic Challenge
Volume: 8 Issue: 2
Author(s): Aldo Leone, Emilio Centaro and Aurelio Leone
Affiliation:
Keywords: Blood Pressure Control, Clinical Trials, Costs, Epidemiological findings, Hypertension, Public Health
Abstract: Hypertension is one of the major risk factors for cardiovascular disease and fatal or non-fatal cardiac and cerebrovascular complications. Kidney and retina are also target organs of blood pressure rise. Progressive changes in the definition of hypertension have occurred in the years and blood pressure 130/85 mm Hg is considered as normal.
Ischaemic heart disease, particularly myocardial infarction, often unrecognized, as well as stroke and transient ischaemic attack may be observed more frequently than other disorders in hypertensive patients.
Conducted large-scale trials do not support the hypothesis that effective benefits are reached by current nonpharmacological or pharmacological prevention although some different opinions exist.
Lowering blood pressure is, however, the main target to reach for reducing cardiovascular complications in hypertensive patients, in anyway that can be obtained. So doing, the ratio cost-benefit could be improved with a reduction of the costs supported by public health for hypertensive individuals.
Export Options
About this article
Cite this article as:
Leone Aldo, Centaro Emilio and Leone Aurelio, The Control of Arterial Hypertension: Epidemiological and Economic Challenge, Current Hypertension Reviews 2012; 8 (2) . https://dx.doi.org/10.2174/157340212800840726
DOI https://dx.doi.org/10.2174/157340212800840726 |
Print ISSN 1573-4021 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6506 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Varicella-Zoster Virus Infections During Pregnancy: Epidemiology, Clinical Symptoms, Diagnosis, Prevention and Therapy
Current Pediatric Reviews Elevated Serum Human Cytomegalovirus IgM Levels in the Acute Phase of Ischemic Stroke are Associated with Increased Risk of Death and Major Disability
Current Neurovascular Research Editorial (Thematic Issues: New Developments in the Medicinal Chemistry of Some Azoles)
Current Topics in Medicinal Chemistry Dynamics of Telomere Length in Different Age Groups in a Latvian Population
Current Aging Science Targeting NO Signaling for the Treatment of Osteoporosis
Current Medicinal Chemistry Editorial [Hot Topic: Cardiac Cell Therapy: anno 2011 (Executive Guest Editor: Sophie Van Linthout)
Current Pharmaceutical Design Possible Direct Influence of Complement 3 in Decreasing Insulin Sensitvity in a Cohort of Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Dynamics of Diabetes and Obesity: An Alarming Situation in the Developing Countries in Asia
Mini-Reviews in Medicinal Chemistry Sorbitol Dehydrogenase: Structure, Function and Ligand Design
Current Medicinal Chemistry Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets Pleiotropic Effects of Statins: Stabilization of the Vulnerable Atherosclerotic Plaque?
Current Pharmaceutical Design Women Tipping the Scale During Pregnancy: A Special Population for Obesity Interventions,Treatments and Clinical Trials
Current Pharmaceutical Design The Effect of Serotonin 5-HT2 Receptor Inhibitor on Vasomotor Responses
Vascular Disease Prevention (Discontinued) Steroid Hybrid Systems: New Molecular Entities with Potential Therapeutical Spectrum
Current Drug Therapy Impact of Omega-3 and Trans Fatty Acids on Vascular Remodeling:Opposing Roles in Cardiovascular Health
Current Enzyme Inhibition MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry